Shots:
- Polpharma has entered into licensing deals with MS Pharma to commercialize PB016 (vedolizumab), PB018 (ocrelizumab), & PB019 (guselkumab) biosimilars across the Middle East & North Africa (MENA) region
- As per the deal, MS Pharma will be responsible for registration, marketing, & distribution of the 3 biosimilars in MENA, while Polpharma will handle development, manufacturing, & supply; fill-finish activities to be transferred to MS’ biologics facility in Saudi Arabia
- Vedolizumab targets α4β7 integrin to treat UC & Crohn’s disease, while ocrelizumab depletes CD20+ B cells to reduce inflammation in multiple sclerosis. Guselkumab blocks IL-23 (p19 subunit) & is approved for plaque PsO & PsA
Ref: Polpharma Biologics | Image: Polpharma Biologics and MS Pharma | Press Release
Related News:- Polpharma Biologics Collaborates with Fresenius Kabi to Commercialize PB016 (Biosimilar, Entyvio)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
